Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: BriBear who wrote (3480)	12/30/1997 8:15:00 PM
From: JOHN W.	Read Replies (2) \| Respond to of 6136

BriBear, good. Viracept has shown better results with Sustiva than Crixivan. I really don't think that will have a large effect on Viracept sales, but just makes David look stupid. Come on David, do the Homework? Are you waiting for Friday to take profits?

To: BriBear who wrote (3480)	12/30/1997 8:55:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 6136

BB: You are bit confused by names. Nucleotide: DNA/RNA base (T, I, A, G, U, C,..) or their analogue + sugar (ribose) + phosphate ester. Nucleoside: DNA/RNA base + sugar Difference in one letter is for phosphorylated compounds. Also, any RT drug have to be phosphorylated (active metabolite in body) before they can do any inhibitory effects. Cidofovir (PMEA) and PMPA are phosphonylmethoxy base derivative and they do not have regular sugar component, or both drug are phosphorylated acyclic nucleotide. So this drug is already active inhibitor, compared to other RT drug. mz

To: BriBear who wrote (3480)	12/31/1997 12:45:00 PM
From: Oliver & Co	Read Replies (1) \| Respond to of 6136

"Johns Hopkins AIDS Program for Medicaid Patients Efficacious and Cost-Effective" Reuters Health Information Services (12/30/97) ÿÿÿÿ An article in the December 25th issue of Disease Management News indicates that a new AIDS program for Medicaid patients has both saved money and increased patient survival. The article noted that while Medicaid pays nearly $23,000 per patient for AIDS patients nationwide each year, the average cost of treatment with the Moore Options AIDS program at Johns Hopkins Hospital in Maryland is only about $10,000 per patient per year. According to Dr. John Bartlett, head of the infectious disease division at the university, the AIDS program helped increase the survival rate of AIDS patients from inner-city Baltimore, so that patients in that system had the same likelihood of survival, regardless of earnings, gender, race, or risk level. ====================================================================== I wonder what combos they are giving patients, to be able to have such low cost.